Carnosine: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข4 clinical studies cited
- โขOverall evidence level: moderate
- โข7 research gaps identified
Research Studies
L-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes
Houjeghani S, Kheirouri S, Faraji E, Jafarabadi MA (2018) โข Nutrition Research
Double-blind, placebo-controlled RCT in 54 patients with type 2 diabetes receiving 1 g/day L-carnosine or placebo for 12 weeks. Carnosine significantly reduced fasting glucose, HbA1c, triglycerides, AGE markers, and TNF-alpha compared to placebo.
Key Findings
- Significant reduction in fasting blood glucose (13.1 mg/dL) in carnosine group vs placebo
- Significant reduction in HbA1c (0.6%) in carnosine group vs placebo
- Significant reduction in serum carboxymethyl lysine (AGE marker) of 91.8 ng/mL
- Significant reduction in triglycerides (29.8 mg/dL) and TNF-alpha
- Significant reduction in serum pentosidine (AGE marker) within carnosine group
Limitations: Small sample size (n=54); 12-week duration; single-center study; no long-term follow-up; diet not strictly controlled
Carnosine supplementation improves glucose control in adults with pre-diabetes and type 2 diabetes: A randomised controlled trial
de Courten B, Jakubova M, de Courten MPJ, et al. (2024) โข Nutrition Metabolism and Cardiovascular Diseases
Randomized controlled trial in 43 adults with prediabetes or type 2 diabetes who consumed 2 g/day carnosine or placebo for 14 weeks. Carnosine reduced glucose at 90 and 120 minutes during OGTT and total glucose area under the curve.
Key Findings
- Decreased blood glucose at 90 min (-1.31 mmol/L, p=0.02) and 120 min (-1.60 mmol/L, p=0.02) during OGTT
- Reduced total glucose area under the curve (-3.30 mmol/L, p=0.04)
- No changes in insulin secretion, suggesting hepatic glucose output mechanism
- No adverse events during the 14-week intervention period
Limitations: Small sample size (n=43); no long-term follow-up; mechanism not fully elucidated; secondary analysis of larger trial
The therapeutic potential of carnosine/anserine supplementation against cognitive decline: A systematic review with meta-analysis
Caruso G, Caraci F, Jolivet RB (2021) โข Biomedicines
Systematic review with meta-analysis of carnosine/anserine supplementation for cognitive decline. Analysis of 5 RCTs found that 1 g/day for 12 weeks improved global cognitive function in elderly subjects and MCI patients.
Key Findings
- 1 g/day carnosine/anserine for 12 weeks improved global cognitive function
- Effective in both healthy elderly and mild cognitive impairment patients
- No significant effects detected on depressive symptoms
- PRISMA-compliant review of 516 initially identified studies, 5 included
Limitations: Only 5 studies met inclusion criteria; 3 provided sufficient data for quantitative meta-analysis; small total sample sizes; all studies used 12-week duration; heterogeneity in carnosine vs anserine formulations
Efficacy of N-acetylcarnosine in the treatment of cataracts
Babizhayev MA, Deyev AI, Yermakova VN, et al. (2002) โข Drugs in R&D
Randomized placebo-controlled study of 1% N-acetylcarnosine eye drops in 49 subjects (76 eyes) with age-related cataracts over 6 and 24 months. Reported improvements in visual acuity and glare sensitivity. However, subsequent Cochrane review questioned the quality of evidence.
Key Findings
- 90% of NAC-treated eyes showed improved best corrected visual acuity (7-100%) at 6 months
- 88.9% showed improvement in glare sensitivity (27-100%) at 6 months
- Benefits sustained at 24 months with no worsening of vision in treated eyes
- Reduced posterior subcapsular lens opacity on topographic studies
Limitations: Limited sample size; methodological concerns raised by Cochrane review (PMID 28245346); studies primarily from same research group; no independent replication; Cochrane concluded insufficient evidence to confirm NAC reverses or prevents cataract
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 100+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขLarge-scale phase 3 RCTs needed for diabetes and cognitive function indications
- โขLong-term safety and efficacy data beyond 14 weeks largely absent
- โขOptimal dosing for different indications not established through dose-ranging studies
- โขImpact of CN1 genetic polymorphisms on treatment response not systematically studied
- โขCarnosinase-resistant analogs need clinical development for improved bioavailability
- โขHead-to-head comparison with beta-alanine supplementation for anti-glycation effects not conducted
- โขMechanism of glucose-lowering effect (hepatic glucose output) requires further characterization
Research Overview#
Carnosine has been the subject of scientific investigation for over a century, but rigorous clinical trial evidence has only emerged in the past decade. The evidence base now includes multiple randomized controlled trials in glycemic control, a systematic review with meta-analysis for cognitive function, and controversial studies of N-acetylcarnosine for cataracts. The evidence level is classified as moderate, reflecting the existence of positive RCT data tempered by small sample sizes and limited replication.
Glycemic Control and Diabetes#
Houjeghani et al. (Nutrition Research 2018)#
This double-blind, placebo-controlled RCT (PMID 29420997) is the most comprehensive trial of carnosine in type 2 diabetes. Key design and results:
- Population: 54 patients with T2D (27 carnosine, 27 placebo)
- Intervention: 1 g/day L-carnosine (two 500 mg capsules) for 12 weeks
- Primary outcomes: Fasting glucose reduced by 13.1 mg/dL vs placebo; HbA1c reduced by 0.6%
- AGE markers: Serum carboxymethyl lysine reduced by 91.8 ng/mL; pentosidine significantly reduced within-group
- Inflammatory markers: TNF-alpha significantly reduced
- Lipids: Triglycerides reduced by 29.8 mg/dL
The reduction in AGE markers supports carnosine's anti-glycation mechanism of action in a clinical setting, connecting the well-characterized in vitro activity to human disease biomarkers.
de Courten et al. (NMCD 2024)#
This RCT (PMID 38172006) used a higher dose in a prediabetes/early T2D population:
- Population: 43 adults with prediabetes or T2D
- Intervention: 2 g/day L-carnosine for 14 weeks
- Key finding: Significant reduction in glucose at 90 and 120 minutes during 75g OGTT
- Mechanistic insight: No changes in insulin secretion, suggesting the glucose-lowering effect operates through hepatic glucose output rather than beta-cell function
- Safety: No adverse events reported during the intervention
Systematic Review (PMID 34333586)#
A systematic review and meta-analysis of carnosine and beta-alanine supplementation on glycemic markers found a consistent trend toward improved glycemic control, though the authors noted significant heterogeneity across studies and the need for larger trials.
Cognitive Function#
Caruso et al. Meta-Analysis (Biomedicines 2021)#
This PRISMA-compliant systematic review (PMID 33806459) pooled data from RCTs investigating carnosine/anserine supplementation for cognitive decline:
- Search yield: 516 studies identified, 5 met inclusion criteria, 3 included in quantitative meta-analysis
- Intervention: 1 g/day carnosine or carnosine/anserine for 12 weeks
- Populations: Healthy elderly subjects and patients with mild cognitive impairment
- Result: Significant improvement in global cognitive function scores
- Negative finding: No significant effect on depressive symptoms
The mechanism of cognitive benefit may involve carnosine's anti-glycation and antioxidant activity in the brain, where homocarnosine (GABA-histidine) is the predominant histidine dipeptide. Oral carnosine supplementation may support brain carnosine levels through precursor supply.
Cataract Research#
N-Acetylcarnosine Eye Drops (Drugs R&D 2002)#
The Babizhayev group (PMID 12001824) reported striking results with 1% NAC eye drops:
- 90% improvement in visual acuity at 6 months
- Benefits maintained at 24 months
- NAC serves as a prodrug that delivers carnosine to the lens while bypassing carnosinase
However, a 2017 Cochrane systematic review (PMID 28245346) found "no convincing evidence that NAC reverses cataract, nor prevents progression of cataract." The reviewers noted that the primary evidence comes from a single research group, with no independent replication. The American Academy of Ophthalmology does not recommend NAC eye drops for cataract treatment.
Preclinical Research Highlights#
Neuroprotection#
A phase 1 safety study of IV carnosine in acute ischemic stroke (Stroke 2013) found the compound was safe and well tolerated, providing preliminary safety data for potential neurological applications. Preclinical studies in rodent stroke models showed neuroprotective effects.
Exercise Performance#
The relationship between muscle carnosine and exercise performance is well established through the beta-alanine supplementation literature. A meta-analysis of 40 studies (1,461 participants) demonstrated significant improvement in exercise performance, with the greatest benefits for exercise bouts lasting 0.5-10 minutes where intracellular buffering is most relevant.
Evidence Quality Assessment#
| Evidence Criterion | Assessment | Details |
|---|---|---|
| Study design | RCTs available | Multiple double-blind placebo-controlled trials |
| Sample sizes | Small | Largest trial n=54; most under 50 participants |
| Publication quality | Moderate-High | Published in peer-reviewed journals |
| Mechanism | Well-characterized | Anti-glycation, pH buffering, antioxidant clearly defined |
| Consistency | Moderate | Diabetes and cognitive results consistent; cataract disputed |
| Clinical translation | Dietary supplement | Available OTC; no pharmaceutical development |
| Safety data | Good | Well tolerated up to 2 g/day in multiple trials |
| Independent replication | Limited | Diabetes results partially replicated; cataract not replicated |
Related Reading#
Frequently Asked Questions About Carnosine
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.